Recursion Pharmaceuticals, Inc. · NASDAQ:RXRX
Recursion Pharmaceuticals — Q3 2026 Earnings Presentation
52 slides from Recursion Pharmaceuticals's earnings presentation, Nov 3, 2026

Slide 1: Earnings 3Q26
Earnings 3Q26 November 3, 2026 1

Slide 2: Important Information
Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion cont ain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words s

Slide 3: From innovation to impact: How we develop differentiated medicines
From innovation to impact: How we develop differentiated medicines Connecting discovery, molecular design and clinical development Deliver Design Generate clinical evidence and advance toward patient impact Translate novel targets into Discover differentiated molecules Uncover novel, causal biology

Slide 4: From innovation to impact: Proof points are stacking up
From innovation to impact: Proof points are stacking up Compelling medicines emerging from one repeatable engine Connecting discovery, molecular design and clinical development Deliver Design Generate clinical evidence and advance toward patient impact Translate novel targets into Discover different

Slide 5: One connected AI engine, continuously learning across biology, chemistry, and the clinic
One connected AI engine. Continuously learning across biology, chemistry, and the clinic PROPRIETARY CONNECTED AI DIFFERENTIATED DATA FACTORY PRODUCT ENGINE CLINICAL PIPELINE Industrial-scale Potential first-in- experiments class assets BIOLOGY AI DESIGN AI CLINICAL AI Disease-relevant maps Discover

Slide 6: Clinical proof points emerging from two first-in-class programs
Clinical proof points emerging from two first-in-class programs Early evidence across FAP and solid tumors REC-4881 | FAP PHASE 2 REC-1245 | Solid tumors PHASE 1 Deep, durable activity throughout the GI tract Early monotherapy activity in heavily pretreated patients AI-ENABLED BIOLOGICAL INSIGHT AI-

Slide 7: Progress across partnerships, platform and financial strength
Progress across partnerships, platform and financial strength PARTNER DELIVERY PLATFORM ENGINE FINANCIAL STRENGTH $535M+ DATA FACTORY → CLOSED Into 2029 total partner inflows to date expected cash runway $100M+ from 9 progress-based milestones in LOOP AI PRODUCT ENGINE following October 2026 financi

Slide 8: Recursion announces Sanofi options potential first-in-class immunology development candidate
Recursion announces Sanofi options potential first-in-class immunology development candidate from our collaboration advancing across our collaboration, this milestone is another Potential first-in-class, oral, important demonstration of how our platform can translate computational capabilities into

Slide 9: Roche highlights our Biology Engine's role in an "undruggable" cancer pathway
Roche highlights our Biology Engine's role in finding a unique mechanism for an "undruggable" cancer pathway Presented at Roche Pharma Day on September 28 th, 2026 9

Slide 10: Roche and Genentech: Collaborative process to generate and validate neuroscience targets
Roche and Genentech: Collaborative process to generate and validate neuroscience targets 1. Builds disease-relevant 2. Explores the human human models with high- genome at scale dimensional data Next steps: Output: Unexplored biology Output: Disease-relevant emerges from maps, reviewed biology at un

Slide 11: Recursion appoints Fred Hassan as Chair of the Board
Recursion appoints Fred Hassan as Chair of the Board Four decades in pharma leadership Proven track record of company transformations Experience with innovative business models Fred Hassan Board, data and investing insights Chair of the Board effective October 31, 2026 11

Slide 12: Internal Pipeline
Today’s news Internal Pipeline

Slide 13: Advancing a focused pipeline of AI-enabled, differentiated programs
Advancing a focused pipeline of AI-enabled, differentiated programs AI enabled differentiation Disease Addressable Late indication(s) patients discovery Preclinical Phase 1/2 Pivotal Next catalyst Biology Design Clinical REC-4881 Familial adenomatous MEK1/2 (Oral) >50,0001 2H26: FDA update polyposis

Slide 14: REC-4881
Translating proof to products REC-4881 MEK1/2

Slide 15: 30th CGA-IGC Annual Meeting: REC-4881 Data Summary
30th CGA-IGC Annual Meeting, Denver REC-4881 Data Summary • Leading annual meeting dedicated specifically to • Reductions in larger, higher-risk polyps observed hereditary GI cancer syndromes including FAP • Combined findings support activity across the • Highly targeted audience: Connects the entir

Slide 16: REC-4881: Potential to transform FAP care
Data Cutoff Date: 10-Sep-2026 REC-4881: Potential to transform FAP care Study eligibility expanded to adults 18 years and older • 87%1 with reductions in total polyp burden2 Rapid reductions • 1 in 3 achieved ≥65% reduction after 12 weeks of that persist off treatment (47% median reduction) On REC-4

Slide 17: FAP: a serious, lifelong chronic disease with zero approved therapies
FAP: a serious, lifelong chronic disease ~$15B with zero approved therapies ’26 Total Addressable FAP market (US + EU5)3 EPIDEMIOLOGY UNMET NEED & BURDEN OF CARE >50K US + EU5 Diagnosed FAP patients 0 approved therapies 1 No approved pharmacologic treatments for FAP-associated duodenal polyposis Inh

Slide 18: Disease challenge: Upper GI is the greatest unmet need in FAP
Disease challenge: Upper GI is the greatest unmet need in FAP The majority of polyp burden in post-colectomy patients is found in the upper GI No approved therapies Polyp shape and thin duodenal walls complicate Management relies on lifelong surveillance and repeated upper GI polyp removal endoscopy

Slide 19: REC-4881: Potential to transform $15B FAP market opportunity
REC-4881 | Potential to transform $15B FAP market opportunity US + EU5 FAP ADDRESSABLE MARKET1 POTENTIAL LIFETIME IMPACT OF REC-4881 Estimated prevalence ~67,100 Reduce repeated interventions Potential to reduce surveillance frequency and repeated endoscopic procedures Diagnosed prevalence2 ~55,700

Slide 20: Recursion's platform uncovered a novel therapeutic opportunity in FAP
Recursion’s platform uncovered a novel therapeutic opportunity in FAP Novel insight uncovered by platform Mechanistic rationale for REC-4881 Unbiased phenotypic screening Initiation pathway Evolution pathway Proprietary AI foundation models analyzed cellular images to APC mutation Additional mutatio

Slide 21: REC-4881 drives significant reductions in total polyp burden after 12 weeks
Data Cutoff Date: 10-Sep-2026 Week 13 polyp burden reduction | REC-4881 drives significant reductions in total polyp burden after 12 weeks of treatment Study eligibility expanded to adults 18 years and older 87% 100% Week 13 total polyp burden reduction relative to baseline (n=15 1) Had a reduction

Slide 22: Treatment effect persists after 12 weeks off treatment
Data Cutoff Date: 10-Sep-2026 Week 25 polyp burden reduction | Treatment effect persists after 12 weeks off treatment 11 of 13 patients remained below baseline at Week 25 % change from baseline in total polyp burden in post- colectomy patients at Wk. 13 and Wk. 25 12 weeks ON REC-4881 12 weeks OFF R

Slide 23: REC-4881 reduced number of >5 mm polyps in 6 of 8 patients
Data Cutoff Date: 10-Sep-2026 REC-4881 reduced number of >5 mm polyps in 6 of 8 patients % change from baseline to Week 13 in count of polyps >5 mm across entire GI tract (n=8) Patients with at least one polyp >5 mm at baseline 4→7→3 75% 50% 75% 4 patients had reductions of ≥80% at Week 13 25% 0% 0%

Slide 24: Week 13 upper GI: Nearly 1 in 2 patients achieved ≥65% reductions
Data Cutoff Date: 10-Sep-2026 Week 13 - upper GI | Nearly 1 in 2 (46%) patients achieved ≥65% reductions in upper GI polyp burden Week 13 upper GI polyp burden reduction (n=131) 92% 20% * Had a reduction in upper GI polyp burden 9% * * * 0% -2% -11% -25% -34% -20% ≥65% -47% -55% -68% Polyp burden -7

Slide 25: Week 25 upper GI: Polyp burden reductions persist after 12 weeks off
Data Cutoff Date: 10-Sep-2026 Week 25 – upper GI | Polyp burden reductions persist after 12 weeks off treatment 11 of 12 patients remained below baseline at Week 25 % change from baseline in upper GI polyp burden in post-colectomy patients at Wk. 13 and Wk. 25 92% 12 weeks ON REC-4881 12 weeks OFF R

Slide 26: Additional detail on highest Week 13 responder
Data Cutoff Date: 10-Sep-2026 Additional detail on highest Week 13 responder The result presented here is only for one out of the 16 total efficacy evaluable patient population; this result is not representative of the overall efficacy of the evaluable patient population to date Total polyp burden (

Slide 27: Spigelman staging is used by clinicians to classify disease severity
Spigelman staging is used by clinicians to classify disease severity and inform need for interventions, including surgery Spigelman stage grades duodenal & ampullary disease; clinically, it drives how often patients are scoped and when surgery is needed Stage 0 Stage I Stage II Stage III Stage IV <5

Slide 28: Week 13 Spigelman stage: 50% achieved downstaging
Data Cutoff Date: 10-Sep-2026 Week 13 Spigelman stage: 50% achieved Spigelman downstaging at Week 13, reflecting upper GI disease improvement Baseline Week 13 Week 25 Week 13 | ON TREATMENT III III III I N/A1 II 6 of 12 patients achieved ≥1-stage 50% Spigelman downstaging III II II II II II III II I

Slide 29: Lower GI: 82% of patients had reductions in polyp burden after 12 weeks
Data Cutoff Date: 10-Sep-2026 Lower GI | 82% of patients had reductions in polyp burden from baseline after 12 weeks of treatment ~1 in 3 patients with ≥65% polyp burden reduction from baseline 1 Week 13 lower GI polyp burden reduction (n=112) 150% 25% 141% 33% * * * 0% -15% -20% -25% -50% -50% -57%

Slide 30: Lower GI: Polyp burden remained below baseline in 70% of patients off drug
Data Cutoff Date: 10-Sep-2026 Lower GI | Polyp burden in the lower GI remained below baseline in 70% of patients 12 weeks after stopping REC-4881 Lower GI polyp burden reduction Week 13 & Week 25 12 weeks ON REC-4881 12 weeks OFF REC-4881 375% Large % increase from baseline of Key findings % change

Slide 31: Favorable safety profile supports potential for chronic dosing
Data Cutoff Date: 10-Sep-2026 Favorable safety profile supports potential for chronic dosing REC-4881 4 mg QD 80.8% patients had TRAEs ≤ Grade 2 consistent with mechanism of Event, n (%) (N=26 safety evaluable)1 MEK1/2 inhibition Any TEAE related to Most common TRAEs Grade 1/2 25 (96.2) study drug (

Slide 32: Conclusions
Data Cutoff Date: 10-Sep-2026 Conclusions Natural history analysis demonstrates consistent progression in polyp burden over time, contextualizing polyp burden reductions driven by REC-4881 REC-4881 safety • Favorable safety profile; AEs consistent with the MEK1/2 inhibitor class • Treatment-related

Slide 33: FAP Deep Dive
Today’s news FAP Deep Dive

Slide 34: KOL Panel: Today's speakers
KOL Panel: Today’s speakers Evelien Dekker, MD, PhD Head of Expert Clinic for Familial and Hereditary Polyposis and Colorectal Cancer, and Professor of Gastrointestinal Oncology, Amsterdam University Medical Center • Practicing gastroenterologist and professor of gastrointestinal oncology. • Researc

Slide 35: Patient Panel: Today's speakers
Patient Panel: Today’s speakers Laura and Jesse Laster • Jesse grew up with a strong family history of FAP, undergoing a colectomy as a teenager. • Facing a high continued cancer risk post-colectomy after high-grade dysplasia was found, he underwent a Whipple procedure, requiring the removal of his

Slide 36: REC-1245
Translating proof to products REC-1245 First-in-class RBM39 degrader

Slide 37: REC-1245: Novel biology with early clinical activity
Data Cutoff Date: 21-Aug-2026 REC-1245: Novel biology with early clinical activity Phase 1 monotherapy results support expansion at 45 mg once daily Novel Oral RBM39 degrader targeting vulnerabilities in hard-to-treat cancers mechanism with Disrupts splicing of transcripts associated with stress-res

Slide 38: RBM39: Oncology target with broad potential across multiple tumor types
RBM39: Oncology target with broad potential based on highly relevant mechanism in multiple tumor types Recursion OS Insight RBM39 is a master splicing factor REC-1245 CDK13 CDK12 RBM39 RBM39 • Potential first-in-class molecular glue degrader RBM39 ensures proper RBM39 splicing of critical • Oral, hi

Slide 39: RBM39: A broad opportunity in hard-to-treat cancers
RBM39: A broad opportunity in hard-to-treat cancers Targeting RBM39 is relevant across multiple indications >100k Hard to treat tumors Including endometrial, hepatocellular (HCC) and ovarian cancers Total addressable patients/yr (US + EU5)1 Transcriptionally driven cancers Including pediatric tumors

Slide 40: REC-1245 Phase 1 dose escalation update
Data Cutoff Date: 21-Aug-2026 REC-1245 Phase 1 dose escalation update Early activity from monotherapy dose escalation Phase 1A monotherapy Continuous once-daily dosing Emerging response and safety data Dose 5 QD • Multiple partial responses at doses ≥45 mg* Dose 4 QD Dose 6 QD1 (45 mg) • Activity ac

Slide 41: REC-1245: Safety & treatment-related adverse events (TRAEs)
Data Cutoff Date: 21-Aug-2026 REC-1245: Safety & treatment-related adverse events (TRAEs) All doses (N=30) TRAE Any grade Grade ≥3 45 mg once daily (N=10) Any TRAE 22 (73.3%) 8 (26.7%) • No dose-limiting toxicities (DLTs) Fatigue 9 (30%) 0 • No serious TRAEs Anemia 9 (30%) 3 (10%) Nausea 6 (20%) 1 (

Slide 42: REC-1245: Three partial responses in endometrial and liver cancer
Data Cutoff Date: 21-Aug-2026 REC-1245: Three partial responses in endometrial and liver cancer Target lesion change by starting dose in response evaluable patients at 45 mg and 65 mg (N=12) 16.0% 20% (BRCA) 8.9% 91.7% DCR at 8 weeks5 (11/12) (EC) 3.0% (EC) (LC) 0.0% 1.5% % change from baseline (EC)

Slide 43: REC-1245: Confirmed partial response in endometrial cancer
Data Cutoff Date: 21-Aug-2026 REC-1245: Confirmed partial response in endometrial cancer Baseline CT Scan Week 9 CT Scan Week 17 CT Scan Patient details 1 Lung Mets • 70-year-old female with recurrent, progressive Stage IV high- grade serous carcinoma of the endometrium • p53-mutant / HER2 non-ampli

Slide 44: REC-1245: Confirmed partial response in endometrial cancer
Data Cutoff Date: 21-Aug-2026 REC-1245: Confirmed1 partial response in endometrial cancer Patient details2 • 54-year-old female with recurrent, progressive Stage IV Baseline CT Scan Week 9 CT Scan Week 13 CT Scan endometrioid carcinoma of the endometrium • p53-mutant / HER2 amplified, ER+, PR-, MMR

Slide 45: Significant opportunity for differentiated oral therapy in endometrial cancer
Significant opportunity for differentiated oral therapy in endometrial cancer Actively enrolling in endometrial cancer, data expected in 2H27 Limited treatment 4th 1 ~68K 1 ~20% 2 options in 2L+3 most common estimated new US 5-year relative for patients relapsing on cancer in US women cases in 2026

Slide 46: Financials & Looking ahead
Financials & Looking ahead

Slide 47: A more focused Recursion
A more focused Recursion Capital discipline to fund the highest-value opportunities FINANCIAL STRENGTH & OPERATING DISCIPLINE $749M <$375M <$360M Pro forma cash and cash equivalents¹ 2026 OpEx guidance, 40% lower 2027 OpEx guidance2 cash OpEx vs. 2024² Following oversubscribed financing, cash runway

Slide 48: Continued momentum with upcoming catalysts
Continued momentum with upcoming catalysts Deliver Generate clinical evidence and advance Design toward patient impact Translate novel targets into Discover differentiated molecules Delivered Uncover novel, causal REC-4881 biology Deep, durable polyp reductions Delivered Sanofi REC-1245 Delivered Or

Slide 49: 49
49

Slide 50: Thank you
é ) . re 4 aw ay ; we 54", ee - = Bees ¢ - 2 ; F al * (ann ; er" a t > ‘a rr? | ¥ > * i 4 nin NY is ~ ’ vaca’ € 1

Slide 51: Recursion
O Recursion.

Slide 52: Appendix: Non-GAAP Financial Measures
Appendix Non-GAAP Financial Measures To supplement our financial statements prepared in accordance with U.S. GAAP, we monitor and consider operating cash expense, which is a non-GAAP financial measure. We define operating cash expense as the net cash used in operating activities, excluding non-ordin
Source: 6ix earnings call
More decks from Recursion Pharmaceuticals, Inc.
Investor Presentation (October 2026)44 slides · Oct 15, 2026
Corporate Update (August 2026)66 slides · Aug 5, 2026
Q2 2026 Earnings Presentation38 slides · Aug 5, 2026
Q1 2026 Earnings Presentation34 slides · May 6, 2026
Q1 2026 Earnings Presentation70 slides · May 6, 2026
Q4 2025 Earnings Presentation44 slides · Feb 25, 2026